药 物 回 收
|
| |
| Canada: Rhinaris Nasal Mist: One lot recalled due to risk of microbial growth which may lead to infection (English only) |
| |
Health Canada announces that the Pendopharm Division of Pharmascience Inc. is recalling one lot of Rhinaris Nasal Mist 30 mL (Lot number: 230391A) due to the risk of microbial growth. Using a product contaminated with microbes may lead to rhinosinusitis (a sinus infection). Children, pregnant people, seniors and people with weaker immune systems may be more susceptible to infection or complications from microbial contamination.
Rhinaris Nasal Mist is an over-the-counter drug used to moisturize and lubricate dry nasal passages in adults and children at least two years of age.
The company's testing showed that the preservative in the product may not be as effective as expected, which could lead to an increased risk of growth of microbes such as molds or bacteria over time if they are introduced into the product.
Although rare, rhinosinusitis can lead to more serious complications, such as nasal abscesses (a collection of pus), cellulitis (skin infection) or meningitis (infection and inflammation of the fluid and membranes surrounding the brain and spinal cord).
While the growth of other microbes may be possible, the testing showed that the preservative may not prevent the growth of a specific type of bacteria called Pseudomonas aeruginosa if it is introduced into the product. For someone whose immune system has been weakened by other serious conditions, especially cystic fibrosis, HIV/AIDS, severe lung disease, cancer, diabetes, or burns, Pseudomonas aeruginosa can cause serious infections including pneumonia, bone infections, urinary tract infections, gastrointestinal infections, meningitis, and blood infections.
Please refer to the following website in Health Canada for details:
http://recalls-rappels.canada.ca/en/alert-recall/rhinaris-nasal-mist-one-lot-recalled-due-risk-microbial-growth-which-may-lead
In Hong Kong, the above product is not a registered pharmaceutical product. Related news was previously issued by Health Canada, and was posted on the Drug Office website on 3 Jul 2023.
Ends/Saturday, Jul 8, 2023
Issued at HKT 12:00
|
| |
|
